Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Denosumab (LY06006) in Healthy Chinese Adults
NCT03427853Phase 1Unknown
- Sponsor
- Luye Pharma Group
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMAB807 in osteoporosis, bone metastases and Giant Cell Tumor of Bone (GCTB) (4 arms), sponsored by Luye Pharma Group. Primary endpoints: Number of patients with treatment related adverse events at 56 days and Number of patients with abnormal laboratory values at 56 days. Status: unknown.
02
Drugs
CMAB807
03
Conditions
osteoporosisbone metastasesGiant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT03427853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427853.